Ed Silverman is a senior writer and Pharmalot columnist at STAT. With over three decades of experience, he specializes in the pharmaceutical industry, covering themes such as pharmaceutical regulation, healthcare administration, and public health. Ed's work has been featured in prominent publications including The Boston Globe, Njarts.net, and Environmental Health News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Ed Silverman's articles predominantly revolve around the healthcare and pharmaceutical industry, with a specific focus on government announcements, legal policy regulations, and data citations. His coverage suggests he would be most receptive to pitches offering insights into regulatory developments impacting the pharmaceutical industry.
Given his coverage of comings and goings within the industry, Ed may also be interested in news relating to executive appointments or departures at prominent pharmaceutical companies.
As there is no specified geographic focus for Ed's work, it is advisable to provide information relevant to global trends or developments within the healthcare and pharmaceutical sector.
This information evolves through artificial intelligence and human feedback. Improve this profile .
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
By: Ed Silverman
HRSA says pilot will improve transparency by providing greater visibility into 340B transactions
The state attorney general was stymied by lower court rulings A divided Michigan Supreme Court ruled on Friday that the state's attorney general may investigate Eli Lilly over its pricing practices for insulin.
By: Ed Silverman
Maker of generic drugs was accused of conspiracy to artificially inflate and manipulate prices
By: Ed Silverman
Amgen disclosed that hackers stole company data and patient health information Good morning, everyone, and welcome to another working week.
Case raised drugmakers' alarm that development decisions could be influenced by fear of legal liability
The Big Beautiful Bill Act allows medicines with multiple orphan indications to remain exempt from Medicare price talks
By: Ed Silverman
Judge tossed a suit claiming CVS conspired to reach deals with drugmakers at expense of Medicare beneficiaries
By: Ed Silverman
Recent changes at the U.S. Patent and Trademark Office are making it harder to challenge pharmaceutical patents, raising concerns that slower generic and biosimilar competition could undermine efforts to lower drug costs while strengthening protections for brand-name innovators.
By: Ed Silverman
Moderna has started first-in-human testing of its mRNA vaccine against Bundibugyo Ebola virus Good morning, everyone, and welcome to the middle of the week.
